Cover Image
Market Research Report
Product code 
1030831

Global Cord Blood and Tissue Banking Industry Report 2021

Published: | BIOINFORMANT WORLDWIDE, LLC | 223 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Cord Blood and Tissue Banking Industry Report 2021
Published: November 15, 2021
BIOINFORMANT WORLDWIDE, LLC
Content info: 223 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Executive Summary

Today, more than 70% of the global cord blood market is controlled by the world's 12 largest cord blood banking operators. For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of merger and acquisition (M&A) activity in recent years, with market leaders gaining market share at the expense of smaller competitors and investors vying for buy-in opportunities. Novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry's market leaders. Meanwhile, new technologies to support ex vivo cord blood expansion are advancing at brisk pace.

Substantial cord blood industry consolidation has happened in recent years and investor appetite for cord blood banks has never been stronger. This is because cord blood banks produce stable subscription revenue from long-term storage contracts. At a fundamental level, cord blood banks are both a real estate play (cryogenic storage facilities) and a regenerative medicine (RM) play.

In addition to an aggressive M&A environment, a growing number of cord blood banks have been venturing into new types of stem cell storage, reproductive services, and related cell therapy applications. Specifically, cord blood, cord tissue, placental tissue, and dental pulp have demonstrated intriguing therapeutic promise, causing storage services for these biomaterials to proliferate.

Cord blood has the potential to be an important source of therapeutic cells for a growing range of regenerative medicine applications. According to ClinicalTrials.gov, there are over 1,300 clinical trials evaluating the use of cord blood stem and progenitor cells. These studies use unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). These studies are targeting clinical indications that range from pulmonary diseases to infertility to orthopedic conditions, but the most common area of research is neurologic conditions-such as cerebral palsy, autism, stroke, and hypoxic ischemic encephalopathy.

Within the research realm, cord blood products (fresh and cryopreserved) are being offered by a diverse range of major market leaders, including Lonza, STEMCELL Technologies, AllCells, and dozens of others. Within the therapeutic realm, a growing number of companies are exploring the development and commercialization of perinatal products across a diverse range of applications.

Cord Blood Report Highlights

Overall, the report answers the following questions:

  • 1. Number of cord blood units cryopreserved in public and private cord blood banks globally
  • 2. Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells
  • 3. Utilization of cord blood cells in clinical trials for developing regenerative medicines
  • 4. The decline of the utilization of cord blood cells in HSC transplantations since 2005
  • 5. Emerging technologies to influence financial sustainability of public cord blood banks
  • 6. The future scope for companion products from cord blood
  • 7. The changing landscape of cord blood cell banking market
  • 8. Extension of services by cord blood banks
  • 9. Types of cord blood banks
  • 10. Economic model of public cord blood banks
  • 11. Cost analysis for public cord blood banks
  • 12. Economic model of private cord blood banks
  • 13. Cost analysis for private cord blood banks
  • 14. Profit margins for private cord blood banks
  • 15. Pricing for processing and storage in private banks
  • 16. Rate per cord blood unit in the U.S. and Europe
  • 17. Indications for the use of cord blood-derived HSCs for transplantations
  • 18. Diseases targeted by cord blood-derived MSCs in regenerative medicine
  • 19. Cord blood processing technologies
  • 20. Number of clinical trials, number of published scientific papers and NIH funding for cord blood research
  • 21. Transplantation data from different cord blood registries

Key questions answered within the report are:

  • 1. What are the strategies being considered to improve the financial stability of public cord blood banks?
  • 2. What are the companion products proposed to be developed from cord blood?
  • 3. How much is spent to process and store a unit of cord blood?
  • 4. How much does a unit of cryopreserved cord blood unit fetch on release?
  • 5. Why do most public cord blood banks incur a loss?
  • 6. What is the net profit margin for a private cord blood bank?
  • 7. What are the prices for processing and storage of cord blood in private cord blood banks?
  • 8. What are the rates per cord blood units in the U.S. and Europe?
  • 9. What are the revenues from cord blood sales for major cord blood banks?
  • 10. Which are the different accreditation systems for cord blood banks?
  • 11. What are the comparative merits of the various cord blood processing technologies?
  • 12. What is to be done to increase the rate of utilization of cord blood cells in transplantations?
  • 13. Which TNC counts are preferred for transplantation?
  • 14. What is the number of registered clinical trials using cord blood and cord tissue?
  • 15. How many clinical trials are studying the ex vivo expansion of cord blood?
  • 16. How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
  • 17. What is the share of cord blood transplants compared to bone marrow and peripheral blood transplants from 2000 to 2021?
  • 18. What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
  • 19. Which are the top ten countries for donating cord blood?
  • 20. What are the diseases targeted by cord blood and tissue derived MSCs within clinical trials?

At 232 pages in length, this global strategic report presents a comprehensive snapshot of the cord blood and tissue banking market. It includes a detailed market size determination, with breakdown by geography, indication, and type of bank, as well as future projections for each segment through 2027. It reveals the number of cord blood units stored in inventory by the largest cord blood banks worldwide, as well as the total storage count for both public and private units in storage worldwide. It also presents the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell transplantation (HSCT).

It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis. It provides coverage of recent M&A transactions, including the consolidation plans executed by the twelve largest cord blood operators worldwide. Although cord blood is now used to treat 80 different diseases, this number will expand as regenerative medicine applications begin to receive approvals in major healthcare markets worldwide.

Given the accelerating complexity and competitive nature of this global market, you don't have the time to do the research. Claim this market report to become immediately informed, without sacrificing hours of unnecessary research. BioInformant has tracked this market since 2006, providing it with an unprecedented 15-year historical data set on which to make future market predictions.

Table of Contents

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction
    • 1.3.1. Cord Blood: An Alternative Source for HPSCs
    • 1.3.2. Utilization of Cord Blood Cells in Clinical Trials
    • 1.3.3. The Struggle of Cord Blood Banks
    • 1.3.4. Emerging Technologies to Influence the Financial Sustainability of Banks
      • 1.3.4.1. Other Opportunities to Improve Financial Stability
      • 1.3.4.2. Scope for Companion Products
    • 1.3.5. Changing Landscape of Cord Blood Cell Banking Market by Geography
    • 1.3.6. Extension of Services by Cord Blood Banks
  • 1.4. Cord Blood Industry: As of Today
    • 1.4.1. Diversification of Services
    • 1.4.2. Pairing with Genetic Testing Services
    • 1.4.3. Pairing with Fertility and Assisted Reproduction Services
    • 1.4.4. Cord Blood Industry Consolidation
    • 1.4.5. Cord Blood Banks as Integrated Therapeutic Companies

2. CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW

  • 2.1. Cord Blood Banking (Stem Cell Banking)
    • 2.1.1. Public Cord Blood Banks
      • 2.1.1.1. Economic Model of Public Cord Blood Banks
      • 2.1.1.2. Cost Analysis for Public Banks
      • 2.1.1.3. Relationship between Costs and Release Rates
    • 2.1.2. Private Cord Blood Banks
      • 2.1.2.1. Cost Analysis for Private Cord Blood Banks
      • 2.1.2.2. Economic Model of Private Banks
    • 2.1.3. Hybrid Cord Blood Banks
  • 2.2. Global Private Cord Blood Banking: Market Leaders
    • 2.2.1. Comparing Cord Blood Banks
    • 2.2.2. Cord Blood Banks in the U.S.
    • 2.2.3. Proportion of Public, Private and Hybrid Banks in U.S.
  • 2.3. Percent Share of Parents of Newborns Storing Cord Blood by Country/Region
  • 2.4. Pricing for Processing and Storage in Commercial Banks
    • 2.4.1. Rate per Cord Blood Unit in the U.S. and Europe
  • 2.5. Cord Blood Revenues for Major Cord Blood Banks

3. CORD BLOOD BANK ACCREDITATIONS

  • 3.1. American Association of Blood Banks (AABB)
  • 3.2. Foundation for the Accreditation of Cellular Therapy (FACT)
  • 3.3. FDA Registration
  • 3.4. FDA Biologics License Application (BLA) License
  • 3.5. Investigational New Drug (IND) for Cord Blood
  • 3.6. Human Tissue Authority (HTA)
  • 3.7. Therapeutic Goods Act (TGA) in Australia
  • 3.8. International NetCord Foundation
  • 3.9. AABB Accredited Cord Blood Facilities
  • 3.10. FACT Accreditation for Cord Blood Banks

4. APPLICATIONS OF CORD BLOOD CELLS

  • 4.1. Hematopoietic Stem Cell Transplantations with Cord Blood Cells
  • 4.2. Umbilical Cord Cells in Regenerative Medicine

5. CORD BLOOD PROCESSING TECHNOLOGIES

  • 5.1. The Process of Separation
    • 5.1.1. PrepaCyte-CB
    • 5.1.2. Advantages of PrepaCyte-CB
    • 5.1.3. Treatment Outcomes with PrepaCyte-CB
    • 5.1.4. Hetastarch (HES)
    • 5.1.5. AutoXpress (AXP)
    • 5.1.6. SEPAX
    • 5.1.7. Plasma Depletion Method (MaxCell Process)
    • 5.1.8. Density Gradient Method
  • 5.2. Comparative Merits of Different Processing Methods
    • 5.2.1. Early Stage HSC Recovery by Technologies
    • 5.2.2. Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood
    • 5.2.3. Late Stage Recovery of HSCs from Cord Blood
  • 5.3. HSC (CD45+) Recovery
  • 5.4. Days to Neutrophil Engraftment by Technology
  • 5.5. Anticoagulants used in Cord Blood Processing
    • 5.5.1. Type of Anticoagulant and Cell Recovery Volume
    • 5.5.2. Percent Cell Recovery by Sample Size
    • 5.5.3. TNC Viability by Time Taken for Transport and Type of Anticoagulant
  • 5.6. Cryopreservation of Cord Blood Cells
  • 5.7. Bioprocessing of Umbilical Cord Tissue (UCT)
  • 5.8. A Proposal to Improve the Utilization Rate of Banked Cord Blood

6. CORD BLOOD CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS & NIH FUNDING

  • 6.1. Cord Blood Cells for Research
  • 6.2. Cord Blood Cells for Clinical Trials
    • 6.2.1. Number of Clinical Trials involving Cord Blood Cells
    • 6.2.2. Number of Clinical Trials using Cord Blood Cells by Geography
    • 6.2.3. Number of Clinical Trials by Study Type
    • 6.2.4. Number of Clinical Trials by Study Phase
    • 6.2.5. Number of Clinical Trials by Funder Type
    • 6.2.6. Clinical Trials Addressing Indications in Children
    • 6.2.7. Select Three Clinical Trials Involving Children
      • 6.2.7.1. Sensorineural Hearing Loss (NCT02038972)
      • 6.2.7.2. Autism Spectrum (NCT02847182)
      • 6.2.7.3. Cerebral Palsy (NCT01147653)
    • 6.2.8. Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue
    • 6.2.9. UCB for Diabetes
    • 6.2.10. UCB in Cardiovascular Clinical Trials
    • 6.2.11. Cord Blood Cells for Auto-Immune Diseases in Clinical Trials
    • 6.2.12. Cord Tissue Cells for Orthopedic Disorders in Clinical Trials
    • 6.2.13. Cord Blood Cells for Other Indications in Clinical Trials
  • 6.3. Major Diseases Addressed by Cord Blood Cells in Clinical Trials
  • 6.4. Clinical Trials using Cord Tissue-Derived MSCs
  • 6.5. Ongoing Clinical Trials using Cord Tissue
    • 6.5.1. Cord Tissue-Based Clinical Trials by Geography
    • 6.5.2. Cord Tissue-Based Clinical Trials by Phase
    • 6.5.3. Cord Tissue-Based Clinical Trials by Sponsor Types
    • 6.5.4. Companies Sponsoring Trials using Cord Tissue-Derived MSCs
  • 6.6. Wharton's Jelly-Derived MSCs in Clinical Trials
    • 6.6.1. Wharton's Jelly-Based Clinical Trials by Phase
    • 6.6.2. Companies Sponsoring Wharton's Jelly-Based Clinical Trials
  • 6.7. Clinical Trials Involving Cord Blood Expansion Studies
    • 6.7.1. Safe and Feasible Expansion Protocols
    • 6.7.2. List of Clinical Trials involved in the Expansion of Cord Blood HSCs
    • 6.7.3. Expansion Technologies
  • 6.8. Scientific Publications on Cord Blood
  • 6.9. Scientific Publications on Cord Tissue
  • 6.10. Scientific Publications on Wharton's Jelly-Derived MSCs
  • 6.11. Published Scientific Papers on Cord Blood Cell Expansion
  • 6.12. NIH Funding for Cord Blood Research

7. PARENT'S AWARENESS AND ATTITUDE TOWARDS CORD BLOOD BANKING

  • 7.1. Undecided Expectant Parents
  • 7.2. The Familiar Cord Blood Banks Known by the Expectant Parents
  • 7.3. Factors Influencing the Choice of a Cord Blood Bank

8. CORD BLOOD: AS A TRANSPLANTATION MEDICINE

  • 8.1. Comparisons of Cord Blood to other Allograft Sources
    • 8.1.1. Major Indications for HCTs in the U.S.
    • 8.1.2. Trend in Allogeneic HCT in the U.S. by Recipient Age
    • 8.1.3. Trends in Autologous HCT in the U.S. by Recipient Age
  • 8.2. HCTs by Cell Source in Adult Patients
    • 8.2.1. Transplants by Cell Source in Pediatric Patients
  • 8.3. Allogeneic HCTs by Cell Source
    • 8.3.1. Unrelated Donor Allogeneic HCTs in Patients <18 Years
  • 8.4. Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity
    • 8.4.1. Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years
  • 8.5. Odds of using a Baby's Cord Blood
  • 8.6. Cord Blood Utilization Trends
  • 8.7. Number of Cord Blood Donors Worldwide
    • 8.7.1. Number of CBUs Stored Worldwide
    • 8.7.2. Number of CBUs, PBSCs and BMCs Shipped
    • 8.7.3. Cord Blood Donors by Geography
      • 8.7.3.1. Public Cord Blood Units Stored in Different Geographies
      • 8.7.3.2. Number of Donors by HLA Typing
    • 8.7.4. Searches Made by Transplant Patients for Donors/CBUs
    • 8.7.5. Types of CBU Shipments (Single/Double/Multi)
    • 8.7.6. TNC Count of CBUs Shipped for Children and Adult Patients
    • 8.7.7. Shipment of Multiple CBUs
    • 8.7.8. Percent Supply of CBUs for National and International Patients
    • 8.7.9. Decreasing Number of CBU Utilization
  • 8.8. Top Ten Countries in Cord Blood Donation
    • 8.8.1. HLA Typed CBUs by Continent
    • 8.8.2. Percentage TNC of Banked CBUs
    • 8.8.3. Total Number of CBUs, HLA-Typed Units by Country
  • 8.9. Cord Blood Export/Import by E.U. Member States
    • 8.9.1. Number of Donors and CBUs in Europe
    • 8.9.2. Number of Exports/Imports of CBUs in E.U.
  • 8.10. Global Exchange of Cord Blood Units

9. CORD BLOOD CELLS AS THERAPEUTIC CELL PRODUCTS IN CELL THERAPY

  • 9.1. MSCs from Cord Blood and Cord Tissue
    • 9.1.1. Potential Neurological Applications of Cord Blood-Derived Cells
    • 9.1.2. Cord Tissue-Derived MSCs for Therapeutic use
      • 9.1.2.1. Indications Targeted by UCT-MSCs in Clinical Trials
  • 9.2. Current Consumption of Cord Blood Units by Clinical Trials
  • 9.3. Leading Cord Blood Stem Cell Treatments in Clinical Trials

The following sections present leading cord blood stem cell treatments that are now being tested in formal clinical trials.

  • 9.3.1. Acquired Hearing Loss (NCT02038972)
  • 9.3.2. Autism (NCT02847182)
  • 9.3.3. Cerebral Palsy (NCT03087110)
  • 9.3.4. Hypoplastic Left Heart Syndrome (NCT01856049)
  • 9.3.5. Type 1 Diabetes (NCT00989547)
  • 9.3.6. Psoriasis (NCT03765957)
  • 9.3.7. Parkinson's Disease (NCT03550183)
  • 9.3.8. Signs of Aging (NCT04174898)
  • 9.3.9. Stroke (NCT02433509)
  • 9.3.10. Traumatic Brain Injury (NCT01451528)

10. MARKET ANALYSIS: Market Size, Segementation, and 5-Year Forecass

  • 10.1. Public vs. Private Cord Blood Banking Market
  • 10.2. Cord Blood Banking Market by Indication

11. PROFILES OF SELECT CORD BLOOD BANKS

  • 11.1. AllCells
    • 11.1.1. Whole Blood
    • 11.1.2. Leukopak
    • 11.1.3. Mobilized Leukopak
    • 11.1.4. Bone Marrow
    • 11.1.5. Cord Blood
  • 11.2. AlphaCord LLC
    • 11.2.1. NextGen Collection System
  • 11.3. Americord Registry, Inc.
    • 11.3.1. Cord Blood 2.0
    • 11.3.2. Cord Tissue
    • 11.3.3. Placental Tissue 2.0
  • 11.4. Be The Match
    • 11.4.1. Hub of Transplant Network
    • 11.4.2. Partners of Be The Match
    • 11.4.3. Allogeneic Cell Sources in Be The Match Registry
    • 11.4.4. Likelihood of a Matched Donor on Be The Match by Ethnic Background
  • 11.5. Biocell Center Corporation
    • 11.5.1. Chorionic villi after Delivery
    • 11.5.2. Amniotic Fluid and Chorionic Villi during Pregnancy
  • 11.6. BioEden Group, Inc.
    • 11.6.1. Differences between Tooth Cells and Umbilical Cord Cells
  • 11.7. Biovault Family
    • 11.7.1. Personalized Cord Blood Processing
  • 11.8. Cell Care
  • 11.9. Cells4Life Group, LLP
    • 11.9.1. Cells4Life's pricing
    • 11.9.2. TotiCyte Technology
    • 11.9.3. Cord Blood Releases
  • 11.10. Cell-Save
  • 11.11. Center for International Blood and Marrow Transplant Research (CIBMTR)
    • 11.11.1. Global Collaboration
    • 11.11.2. Scientific Working Committees
    • 11.11.3. Medicare Clinical Trials and Studies
    • 11.11.4. Cellular Therapy
  • 11.12. Cord Blood Center Group
    • 11.12.1. Cord Blood Units Released
  • 11.13. Cordlife Group, Ltd.
    • 11.13.1. Cordlife's Cord Blood Release Track Record
  • 11.14. Core23 Biobank
  • 11.15. Cord Blood Registry (CBR)
  • 11.16. Cordlife Group, Ltd.
  • 11.17. CordVida
  • 11.18. Crioestaminal
    • 11.18.1. Cord Blood Transplantation in Portugal
  • 11.19. Cryo-Cell International, Inc.
    • 11.19.1. Processing Method
    • 11.19.2. Financial Results of the Company
    • 11.19.3. Cryo-Cell International's Pricing
  • 11.20. CryoHoldco
  • 11.21. Cryoviva Biotech Pvt. Ltd
  • 11.22. European Society for Blood and Bone Marrow Transplantation (EBMT)
    • 11.22.1. EBMT Transplant Activity
  • 11.23. FamiCord Group
  • 11.24. GeneCell International
  • 11.25. Global Cord Blood Corporation (GCBC)
    • 11.25.1. The Company's Business
  • 11.26. HealthBaby Hong Kong
    • 11.26.1. BioArchive System Service Plan
    • 11.26.2. MVE Liquid Nitrogen System
  • 11.27. HEMAFUND
  • 11.28. Insception Lifebank
  • 11.29. LifebankUSA
    • 11.29.1. Placental Banking
  • 11.30. LifeCell International Pvt. Ltd.
  • 11.31. MiracleCord, Inc.
  • 11.32. Maze Cord Blood Laboratories
  • 11.33. New England Cord Blood Bank, Inc.
  • 11.34. New York Cord Blood Center (NYBC)
    • 11.34.1. Products
    • 11.34.2. Laboratory Services
  • 11.35. PacifiCord
    • 11.35.1. FDA-Approved Sterile Collection Bags
    • 11.35.2. AXP Processing System
    • 11.35.3. BioArchive System
  • 11.36. ReeLabs Pvt. Ltd.
  • 11.37. Smart Cells International, Ltd.
  • 11.38. Stem Cell Cryobank
  • 11.39. StemCyte, Inc.
    • 11.39.1. StemCyte Sponsored Clinical Trials
      • 11.39.1.1. Spinal Cord Injury Phase II
      • 11.39.1.2. Other Trials
  • 11.40. Transcell Biolife
    • 11.40.1. ScellCare
    • 11.40.2. ToothScell
  • 11.41. ViaCord
  • 11.42. Vita 34 AG
  • 11.43. World Marrow Donor Association (WMDA)
    • 11.43.1. Search & Match Service
  • 11.44. Worldwide Network for Blood & Marrow Transplantation (WBMT)

INDEX OF FIGURES

  • FIGURE 2.1: Profit Margins of Select Private Cord Blood Banks, 2017-2020
  • FIGURE 2.2: U.S. Cord Blood Banks by Size of Inventory
  • FIGURE 2.3: Proportion of Public, Private and Hybrid Banks in U.S.
  • FIGURE 2.4: Percent Share of Parents of Newborns Storing Cord Blood by Country/Region
  • FIGURE 2.5: Cord Blood Revenues for Companies, 2017-2020
  • FIGURE 3.1: Percent Share of AABB Accredited Cord Blood Facilities by Country
  • FIGURE 5.1: Separation of Buffy Layer
  • FIGURE 5.2: PrepaCyte-CB
  • FIGURE 5.3: Hetastarch (HES)
  • FIGURE 5.4: AutoXpress II
  • FIGURE 5.5: SEPAX 2
  • FIGURE 5.6: Plasma Depletion (PD) Method (MaxCell Process)
  • FIGURE 5.7: Density Gradient Separation of Cord Blood
  • FIGURE 5.8: Early Stage HSC Recovery from Cord Blood by Technologies
  • FIGURE 5.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies
  • FIGURE 5.10: Late Stage HSC Recovery from Cord Blood by Technologies
  • FIGURE 5.11: HSC (CD45+) Recovery Post Process from Whole Blood by Technologies
  • FIGURE 5.12: Days to Neutrophil Engraftment by Technology
  • FIGURE 5.13: Difference in TNC Recovery among Anticoagulants
  • FIGURE 5.14: Type of Anticoagulant and Cell Recovery Volume
  • FIGURE 5.15: Percent Cell Recovery by Sample Size
  • FIGURE 5.16: TNC Viability by Time Taken for Transport
  • FIGURE 5.17: Difference in Recovery of Viable TNC after Thawing
  • FIGURE 5.18: CD34+ Cell Count, CFU and Cell Apoptosis by Cryoprotectants
  • FIGURE 5.19: The Number of Stored and Transplanted CB Units in Korea-CORD by TNC
  • FIGURE 5.20: Number of Stored and Shipped CB Units and Utilization Rate by TNC Count
  • FIGURE 6.1: # of Cord Blood Clinical Trials as Reported in PubMed.gov (2000 to 2020)
  • FIGURE 6.2: Number of Cord Blood Clinical Trials by Geography as of June 2021
  • FIGURE 6.3: Number of Cord Blood Clinical Trials by Study Type as of June 2021
  • FIGURE 6.4: Number of Cord Blood Clinical Trials by Study Phase as of June 2021
  • FIGURE 6.5: Number of Cord Blood Clinical Trials by Funder Type as of June 2021
  • FIGURE 6.6: Percent Share of Indications in Children tested in Clinical Trials
  • FIGURE 6.7: Percent Share of Diseases in Ongoing Clinical Trials using Cord Blood Cells
  • FIGURE 6.8: Percent Share of Diseases in Clinical Trials using MSCs from Cord Tissue
  • FIGURE 6.9: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2021
  • FIGURE 6.10: Cord Tissue-Based Clinical Trials by Study Phase as of June 2021
  • FIGURE 6.11: Cord Tissue-Based Clinical Trials by Funder Type as of June 2021
  • FIGURE 6.12: Wharton's Jelly-Based Clinical Trials by Study Phase as of June 2021
  • FIGURE 6.13: Number of Published Scientific Papers on UCB, 2000-June 2021
  • FIGURE 6.14: Number of Published Scientific Papers on Cord Tissue, 2000-June 2021
  • FIGURE 6.15: Number of Published Scientific Papers on Wharton's Jelly, 2000-June 2021
  • FIGURE 6.16: Number of Published Scientific Papers on CB Expansion, 2000-June 2021
  • FIGURE 7.1: Percent of Expectant Parents Who Have Heard About Cord Blood Banking
  • FIGURE 7.2: Undecided Expectant Parents about Cord Blood Banking
  • FIGURE 7.3: Brand Name Recognition of Cord Blood Banks by Expectant Parents
  • FIGURE 7.4: Factors Influencing the Choice of a Cord Blood Bank
  • FIGURE 8.1: Distribution of Cell Sources in HCTs as Reported in Be The Match
  • FIGURE 8.2: Comparisons of Cord Blood to other Allograft Sources
  • FIGURE 8.3: Major Indications for HTC in the U.S.
  • FIGURE 8.4: Trend in Allogeneic HCT in the U.S. by Recipient Age, 2000 to Present
  • FIGURE 8.5: Trends in Autologous HCT in the U.S. by Recipient Age, 2000 to Present
  • FIGURE 8.6: Transplants by Cell Source in Adult Patients, 2010 to Present
  • FIGURE 8.7: Transplants by Cell Source in Pediatric Patients <18 Years
  • FIGURE 8.8: Allogeneic HCTs by Cell Source Facilitated by NMDP/Be The Match
  • FIGURE 8.9: Unrelated Donor Allogeneic HCTs in Patients <18 Years/NMDP/Be The Match
  • FIGURE 8.10: Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity
  • FIGURE 8.11: Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years
  • FIGURE 8.12: Cumulative Probability of having a Stem Cell Transplant by Age
  • FIGURE 8.13: Cord Blood Utilization Trends
  • FIGURE 8.14: Number of UCB Donors Worldwide as Reported by WMDA, 2000-2020
  • FIGURE 8.15: Number of CBUs Worldwide as Reported by WMDA, 2000-2020
  • FIGURE 8.16: Unrelated BM, PBPC and CB Shipped, 2000-2020
  • FIGURE 8.17: Number of Umbilical Cord Blood Donors by Geography
  • FIGURE 8.18: Public Cord Blood Units Stored by Geography as Reported by the WMDA
  • FIGURE 8.19: Percent Shares of all Registered Donors by HLA Typing Level
  • FIGURE 8.20: Number of Searches Initiated by National Patients for Donors/CBU/Both
  • FIGURE 8.21: Types of CBU Shipments
  • FIGURE 8.22: TNC Count of CBUs Provided for Children and Adult Patients - Single
  • FIGURE 8.23: TNC Count of CBUs Provided for Children and Adult Patients - Multi
  • FIGURE 8.24: Percentage of HPC Products Provided for National and International Patients
  • FIGURE 8.25: Percentage of CB Units Provided for National and International Patients
  • FIGURE 8.26: Top Ten Countries with Number of Donors Listed per 10,000 Inhabitants
  • FIGURE 8.27: Percentage of HLA Typed CBUs Banked per Continent
  • FIGURE 8.28: Percentage TNC of Banked CBUs
  • FIGURE 8.29: Number of Donors per 10,000 Inhabitants by Select E.U. Countries
  • FIGURE 8.30: Global Exchange of Cord Blood Units, 2020
  • FIGURE 8.30: Global Shipments of CBUs by Geography in 2020
  • FIGURE 9.1: Percent Shares of Indications Targeted by UCB-MSCs in Clinical Trials
  • FIGURE 9.2: Percent Share of Clinical Indications using UCT-MSCs
  • FIGURE 9.3: Number of UCB Units Released by Cord Blood Registry by Application
  • FIGURE 10.1: Global Cord Blood Banking Market Revenue by Geography, 2020-2027
  • FIGURE 10.2: Percent Share of Global Cord Blood Banking Market Revenue by Geography
  • FIGURE 10.3: Percent Share of Global Cord Blood Banking Market, Public vs. Private
  • FIGURE 10.4: Percent Share of Cord Blood Banking Market by Indication
  • FIGURE 11.1: Growth of CBUs on the Be The Match Registry, 2001-2020
  • FIGURE 11.2: Diversity of CBUs on Be The Match Registry, 2020
  • FIGURE 11.3: Number of CBUs on Be The Match Registry by Race and Ethnicity, 2020
  • FIGURE 11.4: Diversity of CBUs in Be The Match Registry
  • FIGURE 11.5: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry
  • FIGURE 11.6: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
  • FIGURE 11.7: Percent Recovery of Viable Cells by TotiCyte Technology
  • FIGURE 11.8: Growth in Number of New Transplant Patients Registered with the CIBMTR
  • FIGURE 11.9: New Patients per Year Registered with CIBMTR
  • FIGURE 11.10: Transplant Patients by Graft Source Registered with CIBMTR
  • FIGURE 11.11: Number of Cord Blood Units Stored in CBR and its Competitors
  • FIGURE 11.12: Key Figures of Sales Revenues and Gross Profits for Cordlife, 2014-2020
  • FIGURE 11.13: Cryo-Cell International's Revenues, 2016 to Present
  • FIGURE 11.14: Revenue and Gross Profit for GCBC, 2015-2020
  • FIGURE 11.15: Percent Share of Units Released by Indication
  • FIGURE 11.16: Key Figures of Sales Revenues & Gross Profits for Vita 34, 2014 to Present
  • FIGURE 11.17: Search Types in WMDA Search & Match Service, 2017-2020

INDEX OF TABLES

  • TABLE 2.1: An Overview of Public Cord Blood Banks
  • TABLE 2.2: International Prices of Cord Blood Unit
  • TABLE 2.3: Prices of Cord Blood Units in NMDP Banks in the U.S.
  • TABLE 2.4: An Overview of Private Cord Blood Banks
  • TABLE 2.5: Profit Margins of Select Private Cord Blood Banks, 2017-2020
  • TABLE 2.6: An Overview of Hybrid Cord Blood Banks
  • TABLE 2.7: World's 12 Largest Private Cord Blood Bank Operators
  • TABLE 2.8: Comparison of Three Largest Private Banks in U.S.
  • TABLE 2.9: List of Public, Private and Hybrid Cord Blood Banks in the U.S.
  • TABLE 2.10: Pricing for Storage in Commercial Banks
  • TABLE 2.11: Rate per Cord Blood Unit in the U.S. & Europe
  • TABLE 2.12: Cord Blood Revenues for Major Four Companies, 2017-2020
  • TABLE 3.1: AABB Accredited Cord Blood Facilities
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.2: Select FACT Accredited Cord Blood Facilities
  • TABLE 4.1: Indications for the Use of UCB-Derived Stem Cells for Transplantation
  • TABLE 4.1: (CONTINUED)
  • TABLE 4.1: (CONTINUED)
  • TABLE 4.2: Indications for the Use of UCB-Derived Stem Cells for Regenerative Medicine
  • TABLE 5.1: Advantages of PrepaCyte-CB
  • TABLE 5.2: Treatment Outcomes with PrepaCyte-CB
  • TABLE 6.1: U.S. Cord Blood Banks Supplying Cord Blood for Research
  • TABLE 6.2: Number of Cord Blood Clinical Trials by Geography as of June 2021
  • TABLE 6.3: Number of Cord Blood Clinical Trials by Study Type as of June 2021
  • TABLE 6.4: Number of Cord Blood Clinical Trials by Study Phase as of June 2021
  • TABLE 6.5: Number of Cord Blood Clinical Trials by Funder Type as of June 2021
  • TABLE 6.6: Percent Share of Indications in Children tested in Clinical Trials
  • TABLE 6.7: Select Three Clinical Trials involving Children
  • TABLE 6.8: Ongoing Clinical Trials using UCB for Neurological Diseases
  • TABLE 6.9: Ongoing Clinical Trials using UCB for Diabetes
  • TABLE 6.10: Ongoing Clinical Trials using UCB for Cardiovascular Trials
  • TABLE 6.11: Ongoing Clinical Trials using UCB for Auto-Immune Diseases
  • TABLE 6.12: Ongoing Clinical Trials using UCB for Orthopedic Disorders
  • TABLE 6.13: Ongoing Clinical Trials using UCB for Other Indications
  • TABLE 6.14: Select Clinical Trials using MSCs from Cord Tissue
  • TABLE 6.15: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2021
  • TABLE 6.16: Number of Cord Tissue-Based Clinical Trials by Study Phase as of June 2021
  • TABLE 6.17: Number of Cord Tissue-Based Clinical Trials by Funder Type as of June 2021
  • TABLE 6.18: Select Cord Tissue-Based Clinical Trials by Commercial Entities, 2021
  • TABLE 6.19: Wharton's Jelly-Based Clinical Trials by Phase, June 2021
  • TABLE 6.20: Wharton's Jelly-Based Clinical Trials by Commercial Entities, June 2021
  • TABLE 6.21: Clinical Trials in Cord Blood-Derived Cell Expansion by Country, 2021
  • TABLE 6.22: Clinical Trials of Cell Expansion Studies by Stages in Development, 2021
  • TABLE 6.23: Twenty Clinical Trials involved in the Expansion of Cord Blood HSCs
  • TABLE 6.23: (CONTINUED)
  • TABLE 6.23: (CONTINUED)
  • TABLE 6.23: (CONTINUED)
  • TABLE 6.23: (CONTINUED)
  • TABLE 6.24: Cord Blood Expansion Approaches
  • TABLE 6.25: Select NIH Funding for Umbilical Cord Blood Research, 2019-2020
  • TABLE 8.1: Comparisons of Cord Blood to other Allograft Sources in Transplantation
  • TABLE 8.2: Number of HCTs Performed in the U.S. as reported to CIBMTR by Disease
  • TABLE 8.3: No. of Cord Blood Units Available Worldwide According to WMDA, 1997-2020
  • TABLE 8.4: Unrelated BM, PBPC and CB Shipped, 1997-2020
  • TABLE 8.5: Total Number of Cord Blood Donors and Cord Blood Units by Country
  • TABLE 8.5: (CONTINUED)
  • TABLE 8.5: (CONTINUED)
  • TABLE 8.5: (CONTINUED)
  • TABLE 8.5: (CONTINUED)
  • TABLE 8.5: (CONTINUED)
  • TABLE 8.5: (CONTINUED)
  • TABLE 8.6: Number of Donors and CBUs by E.U. Country as of December 31, 2018
  • TABLE 8.7: Number of Exports/Imports of CBUs in E.U. in 2018
  • TABLE 9.1: Select 15 Clinical Trials Using Cord Blood-Derived MSCs as Interventions
  • TABLE 9.2: Select Clinical Trials using UCT-MSCs as Interventions
  • TABLE 10.1: Global Cord Blood Banking Market Revenue by Geography, 2020-2027
  • TABLE 11.1: AlphaCord's pricing
  • TABLE 11.2: Growth of Cord Blood Units in Be The Match Registry, 2001-2020
  • TABLE 11.3: Diversity of CBUs on Be The Match Registry, 2020
  • TABLE 11.4: Number of CBUs on Be The Match Registry by Race and Ethnicity, 2020
  • TABLE 11.5: Cell Care's pricing for Processing and Storage
  • TABLE 11.6: Cells4Life's pricing for Cord Blood, Cord Tissue, Amnion and Placental Cells
  • TABLE 11.7: Cord Blood and Cord Tissue Products Released from Cells4Life
  • TABLE 11.8: Distribution of Transplant Patients by Graft Source Registered with CIBMTR
  • TABLE 11.9: Distribution of Transplant Patients by Indication Registered with CIBMTR
  • TABLE 11.10: Cord Blood Units Released from Cord Blood Center Group
  • TABLE 11.10: (CONTINUED)
  • TABLE 11.10: (CONTINUED)
  • TABLE 11.11: Cordlife's Cord Blood Release Track Record
  • TABLE 11.11: (CONTINUED)
  • TABLE 11.11: (CONTINUED)
  • TABLE 11.12: Core23 Biobank's Processing and Storage Fees
  • TABLE 11.13: Cryo-Cell International's Revenues, 2016-2020
  • TABLE 11.14: Cryo-Cell International's Pricing for Processing and Storage
  • TABLE 11.15: Allogeneic and Autologous Infusions by Indication Reported in EBMT
  • TABLE 11.16: GeneCell Internationals Prepaid Storage Plans
  • TABLE 11.17: Selected Financial Data for GCBC, 2015-2019
  • TABLE 11.18: Insception Lifebank's Pricing
  • TABLE 11.19: LifeCell International's pricing
  • TABLE 11.20: MiracleCord's Cost Comparison with Competitors
  • TABLE 11.21: Maze Cord Blood Laboratory's Payment Plans
  • TABLE 11.22: Comparison of Pricing of NECBB with others
  • TABLE 11.23: Stem Cell Cryobank's pricing for Processing and Storage
  • TABLE 11.24: Search Types in WMDA Search & Match Service, 2017-2020